Actually I don't think they are in competition. Two different MOA's. One going after early stage Alzheimers, PDD and Rett. The other going after late stage Alzheimer's and Fragile X. Both may go after many other CNS indications as both have an interesting platform.
They could both fail. They could both succeed. That is why there are trials.
Dr. Hampel, currently at the Sorbonne, highlighted their Alzheimer's trial results and AI analysis at a recent World Conference in Spain. And yesterday they announced the addition of a world leader in Parkinson's and DLB to their advisory board. He said that he is VERY impressed by Anavex's clinical data. I think he is honest and sincere...and he certainly has seen data that has not been made public.
*******
Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
NEW YORK – November 8, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dag Aarsland, MD, PhD to its Scientific Advisory Board. Dr Aarsland is Professor and the Head of Department of Old Age Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK. Professor Aarsland is also consultant psychiatrist at the Mental Health for Older Adults and Dementia, South London & Maudsley NHS Foundation Trust, where he leads the Parkinson Spectrum Memory Clinic.
Professor Aarsland earned medical degrees from Universities of Bochum, Germany and Oslo, Norway, with training as a specialist in psychiatry and geriatric psychiatry. He founded and still leads the nationally acclaimed Centre for Age-Related Disease at Stavanger University Hospital. He completed his PhD and became appointed Associate Professor and later Full Professor of Old Age Psychiatry at the University in Bergen, Norway. Later he became Professor at the University of Oslo, before becoming appointed as Professor of Clinical dementia research at the Alzheimer’s Disease Research Centre at the prestigious Karolinska Institute in Stockholm, Sweden. After working in Sweden for five years he moved to his current position at King’s College London.
Professor Aarsland developed and led the European Consortium for dementia with Lewy bodies (DLB), with more than 25 centers across 13 European countries, with a common database of more than 1,200 DLB patients, by far the largest DLB sample in the world. He developed a Parkinson-spectrum Memory Clinic focusing on Parkinson’s disease and dementia with DLB patients. Professor Aarsland played a central role in the study and subsequent paper that lead to the licensing of rivastigmine for Parkinsonian dementia. Professor Aarsland has published more than 400 scientific papers and numerous books and served as an invited speaker at frequent psychiatric and neurological international scientific conferences.
“I am VERY impressed with the scientific and clinical data of ANAVEX®2-73 so far and I am intrigued about the potential outcome on cognition of ANAVEX®2-73 in the ongoing Parkinson’s disease dementia Phase 2 study, since there is such a significant unmet medical need around the globe caused by cognitive impairment, including dementia, and behavioral changes in Parkinson’s patients,” commented Professor Dag Aarsland, MD, PhD.
"The refusal of the real is the number one dogma of our time" Rene Girard
